An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial

An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial

The efficacy of immune checkpoint inhibitors has been shown to depend on preexisting antitumor immunity; thus, their combination with cancer vaccines is an attractive therapeutic approach. Plasmacytoid dendritic cells (PDC) are strong inducers of antitumor responses and represent promising vaccine c...

Full description

Bibliographic Details
Main Authors: Julie Charles, Laurence Chaperot, Dalil Hannani, Juliana Bruder Costa, Isabelle Templier, Sabiha Trabelsi, Hugo Gil, Anaick Moisan, Virginie Persoons, Harald Hegelhofer, Edith Schir, Jean-Louis Quesada, Christophe Mendoza, Caroline Aspord, Olivier Manches, Pierre G. Coulie, Amir Khammari, Brigitte Dreno, Marie-Thérèse Leccia, Joel Plumas
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
plasmacytoid dendritic cells
vaccination
peptide-vaccines
melanoma
clinical study
immunotherapy
immune checkpoint blockers
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1738812

Internet

http://dx.doi.org/10.1080/2162402X.2020.1738812

Similar Items